The paradigm shift from traditional chemotherapy to immunotherapy has boosted the cancer immunotherapy market for the next 10-15 years; according to a research conducted by Kenneth Research.
Manufacturing of new drugs such as monoclonal antibodies for fighting myeloma-related receptors and histone deacetylase (HDAC) inhibitors as well as ongoing studies on similar drugs are the main factors which …
Read More